BioSante Pharmaceuticals, Inc. Joins Russell Microcap Index
June 28 2007 - 7:00AM
Business Wire
BioSante Pharmaceuticals, Inc. (AMEX:BPA) today announced that the
company has been added to the Russell Microcap Index. Stephen M.
Simes, president and CEO of BioSante commented, "We are extremely
pleased to be considered for inclusion within the Russell Microcap�
Index." Simes also added, "This listing is aligned with our goal of
increasing the visibility of BioSante to maximize stockholder
value." The Russell Microcap Index offers investors access to the
microcap segment of the U.S. equity market. It makes up less than
3% of the U.S. equity market and is represented by the smallest
1,000 securities in the small-cap Russell 2000� Index plus the next
1,000 securities. Russell Microcap Index is constructed to provide
a comprehensive and unbiased barometer for the microcap segment
trading on national exchanges, while excluding lesser-regulated OTC
bulletin board securities and pink-sheet stocks due to their
failure to meet national exchange listing requirements. The Russell
Microcap Index is completely reconstituted annually to ensure
larger stocks do not distort performance and characteristics of the
true microcap opportunity set. Russell Investment Group aims to
improve financial security for people by providing strategic
advice, world-class implementation, state-of-the-art performance
benchmarks and a range of institutional-quality investment
products. With more than $200 billion in assets under management,
Russell serves individual, institutional and advisor clients in
more than 40 countries. Founded in 1936, Russell is a subsidiary of
Northwestern Mutual Life Insurance Company. Headquartered in
Tacoma, Washington, Russell has principal offices in Amsterdam,
Auckland, Hong Kong, Johannesburg, London, Melbourne, New York,
Paris, San Francisco, Singapore, Sydney, Tokyo and Toronto.
Russell's indexes are unmanaged and cannot be invested in directly.
For more information on Russell indexes, go to
http://www.russell.com. About BioSante Pharmaceuticals, Inc.
BioSante is developing a pipeline of hormone therapy products to
treat both men and women. These hormone therapy products are gel
formulations for transdermal administration that deliver
bio-identical estradiol and testosterone. BioSante's lead products
include Elestrin (estradiol gel) developed through FDA approval by
BioSante indicated for the treatment of moderate-to-severe
vasomotor symptoms associated with menopause, marketed in the
U.S.�by Bradley Pharmaceuticals, Inc., BioSante's licensee, and
LibiGel� (transdermal testosterone gel) in Phase III development by
BioSante for the treatment of female sexual dysfunction (FSD). Also
in development is Bio-T-Gel�, a testosterone gel for male
hypogonadism, and an oral contraceptive using BioSante patented
technology. The current market in the U.S. for estrogen and
testosterone products is approximately $2.5 billion and for oral
contraceptives approximately $3.0 billion. The company also is
developing its calcium phosphate nanotechnology (CaP) for novel
vaccines, including hepatitis B, avian flu and biodefense vaccines
for toxins such as anthrax, as well as a system for delivering
drugs via alternative routes of administration. Additional
information is available online at www.biosantepharma.com. This
news release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. The
statements regarding BioSante contained in this news release that
are not historical in nature, particularly those that utilize
terminology such as �may,� �will,� �should,� �likely,� �expects,�
�anticipates,� �estimates,� �believes,� �plans,� �hopes,� or
comparable terminology, are forward-looking statements.
Forward-looking statements are based on current expectations and
assumptions, and entail various risks and uncertainties that could
cause actual results to differ materially from those expressed in
such forward-looking statements. Important factors known to
BioSante that could cause actual results to differ materially from
those expressed in such forward-looking statements include the
difficulty of developing pharmaceutical products, obtaining
regulatory and other approvals and achieving market acceptance, the
success of clinical testing, and other factors identified and
discussed from time to time in BioSante's filings with the
Securities and Exchange Commission, including those factors
discussed in BioSante's most recent annual report on Form 10-K and
subsequent quarterly reports on Form 10-Q, which discussions also
are incorporated herein by reference. All forward-looking
statements speak only as of the date of this news release. BioSante
undertakes no obligation to update or revise any forward-looking
statement, whether as a result of new information, future events or
otherwise.
Biosante Pharma (AMEX:BPA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Biosante Pharma (AMEX:BPA)
Historical Stock Chart
From Jul 2023 to Jul 2024